 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- || alclometasone dipropionate ointment/cream / Generic mfg.
Alclometasone for the win🥇 (Twitter) - Jun 28, 2022
- prednisolone / Generic mfg., Aclovate (alclometasone dipropionate ointment/cream) / Novartis
[VIRTUAL] Out with the old and in with the new? Getting the British Society for Cutaneous Allergy corticosteroid series up to scratch () - Sep 9, 2020 - Abstract #BAD2020BAD_207;
Six of eight allergens in the BSCA series had a positive result rate of at least 0.1%, with the exception of prednisolone (0%) and alclometasone dipropionate (0.03%)...They further recommended an extended series to include five newly available allergens with a view to re‐audit in 1 year, so as to rationalize this further. This audit demonstrates the importance of regular assessment of recommended series, to ensure that they reflect clinical practice, to consider newly available allergens and have the best possible detection rate, while being pragmatic about not over‐testing. This update will allow an increased yield of relevant corticosteroid allergy in our patients, and provide a basis for further audit, rationalization and service improvement.
- |||| Vizimpro (dacomitinib) / Pfizer
Trial completion, Enrollment change, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Jun 23, 2015
P2, N=236, Completed, Sponsor: Pfizer
This update will allow an increased yield of relevant corticosteroid allergy in our patients, and provide a basis for further audit, rationalization and service improvement. Active, not recruiting --> Completed | N=184 --> 236
- ||| Vizimpro (dacomitinib) / Pfizer
Enrollment closed, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - May 13, 2015
P2, N=184, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | N=184 --> 236 Recruiting --> Active, not recruiting
- || Vizimpro (dacomitinib) / Pfizer
Trial primary completion date, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Nov 24, 2014
P2, N=184, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Feb 2015
- ||||| alclometasone dipropionate ointment/cream / Generic mfg.
New P2 trial: Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream (clinicaltrials.gov) - Feb 27, 2014
P2, N=310, Completed, Sponsor: GlaxoSmithKline
- ||| Vizimpro (dacomitinib) / Pfizer
Enrollment change, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Jul 22, 2012
P2, N=184, Recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2014 --> Feb 2015 N=240 --> 184
- |||| Vizimpro (dacomitinib) / Pfizer
Enrollment open, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Feb 4, 2012
P2, N=184, Recruiting, Sponsor: Pfizer
N=240 --> 184 Not yet recruiting --> Recruiting
- ||||| Vizimpro (dacomitinib) / Pfizer
New P2 trial, Adverse events, Patient reported outcomes, Metastases: ARCHER 1042: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (clinicaltrials.gov) - Nov 3, 2011
P2, N=184, Recruiting, Sponsor: Pfizer